<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-5366-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CANHERA 150MG VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Trastuzumab
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1364.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Biocon Limited " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Biocon Limited 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 587]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            EBRAHIM M. ALMANA & BROS. CO.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Biocon Biologics Limited 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XC03 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of your medicine is &lsquo;CANHERA 150 mg,150 mg single-dose, containing powder for concentrate for solution for intravenous infusion&rsquo; but in the rest of the leaflet it will be called &ldquo;CANHERA 150 mg&rdquo;.</p><p>- Pharmacotherapeutic group:CANHERA 150 mg belongs to the group of anti-cancer medicines called monoclonal antibodies. It is a manmade antibody developed using molecular cloning and recombinant DNA technology. It is thought to block the HER2 receptors when there is overexpression, thereby blocking growth of the cancer.</p><p>- Therapeutic indications:&nbsp;Early breast cancer, with high levels of a protein called HER2</p><p>Metastic breast cancer (breast cancer that has spread beyond the original tumour) with high levels of HER2. CANHERA 150 mg may be prescribed in combination with the chemotherapy medicine paclitaxel or docetaxel as first treatment for metastatic breast cancer or it may be prescribed alone if other treatments have proved unsuccessful. It is also used in combination with medicines called aromatase inhibitors with patients with high levels of HER2 and hormone receptor-positive metastatic breast cancer (cancer that is sensitive to the presence of female sex hormones).</p><p>Metastatic gastric cancer (stomach cancer that has spread beyond the original tumour) with high levels of HER2, when it is in combination with the other cancer medicines capecitabine or 5- flououracil and cisplatin.</p><p>This medicine is subjected to medicinal prescription.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a. Do not use CANHERA 150 mg if:</p><p>- if you are allergic to trastuzumab, to murine (mouse) proteins, or to any of the other ingredients of trastuzumab (listed in section 6).</p><p>- if you have severe dyspnoea (breathing difficulties) at rest due to complications or advanced malignancy requiring supplementary oxygen therapy.</p><p>- if you are pregnant or breast-feeding your baby.</p><p>b. Take special care with CANHERA 150 mg, if you experience any of the symptoms listed below under warning and precautions.</p><p>c. Warnings and precautions</p><p>Your medication should be initiated under the supervision of your doctor who should be experienced in cancer treatment as the following conditions could occur:</p><p>- If you experience <strong>shortness of breath or trouble breathing, especially with physical exertion, fatigue, swelling in the ankles, feet, legs, abdomen and veins in the attack </strong>(cardiomyopathy).</p><p>- If you experience <strong>flushing, rash, fever, rigors, chills </strong>(signs of infusion-related reactions).</p><p>- If you experience <strong>breathlessness during exercise, dry cough </strong>(signs of pulmonary toxicity).</p><p>- Worsening of chemical treatment-induced lower level of neutrophils (blood cell count).</p><p>d. Heart checks</p><p>Treatment with CANHERA 150 mg alone or with a taxane may affect the heart, especially if you have ever used an anthracycline (taxanes and anthracyclines are two other kinds of medicine</p><p>used to treat cancer).</p><p>The effects may be moderate to severe and could cause death. Therefore, your heart function will be checked before, during (every three months) and after (up to two to five years) treatment with CANHERA 150 mg.</p><p>Talk to your doctor, pharmacist or nurse before you are given CANHERA 150 mg if:</p><p>- You have had taken medications related to any of the heart conditions such as high blood pressure.</p><p>- You have ever had or are currently using a medicine called doxorubicin or epirubicin (medicines used to treat cancer). These medicines (or any other anthracyclines) can damage heart muscle and increase the risk of heart problems with CANHERA 150 mg.</p><p>- You suffer from breathlessness, especially if you are currently using a taxane. CANHERA 150 Mg can cause breathing difficulties, especially when it is first given. This could be more serious if you are already breathless. Very rarely, patients with severe breathing difficulties before treatment have died when they were given CANHERA 150 mg.</p><p>- You have ever had any other treatment for cancer.</p><p>If you receive CANHERA 150 mg with any other medicine to treat cancer, such as paclitaxel, docetaxel, an aromatase inhibitor, capecitabine, 5-fluorouracil, or cisplatin you should also read</p><p>the patient information leaflets for these products.</p><p>e. Children and adolescents</p><p>CANHERA 150 mg is not recommended for anyone under the age of 18 years.</p><p>Other medicines and CANHERA 150 mg</p><p>&bull;Tell your doctor, pharmacist or nurse if you are taking, have recently taken or may take any other medicines.</p><p>&bull;It may take up to 7 months for CANHERA 150 mg to be removed from the body. Therefore, you</p><p>should tell your doctor, pharmacist or nurse that you have had CANHERA 150 mg if you start any</p><p>new medicine in the 7 months after stopping treatment.</p><p>f. Pregnancy</p><p>- If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.</p><p>- You should use effective contraception during treatment with CANHERA 150 mg and for at least 7 months after treatment has ended.</p><p>- Your doctor will advise you of the risks and benefits of taking CANHERA 150 mg during pregnancy. In rare cases, a reduction in the amount of (amniotic) fluid that surrounds the developing baby within the womb has been observed in pregnant women receiving CANHERA 150 mg .</p><p>This condition may be harmful to your baby in the womb and has been associated with the lungs not developing fully resulting in fetal death.</p><p>f. Breast-feeding:</p><p>Do not breast-feed your baby during CANHERA 150 mg therapy and for 7 months after the last dose of CANHERA 150 mg as CANHERA 150 mg may pass to your baby through your breast milk.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>g. Driving and using machines</p><p>It is not known whether CANHERA 150 mg can affect your ability to drive a car or operate machines. However, if during treatment you experience symptoms, such as chills or fever, you should not drive or use machines until these symptoms disappear.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>4. How to take CANHERA 150 mg</p><p>CANHERA 150 mg will be administered to you by your doctor who should be experienced in cancer treatment. Before starting trastuzumab treatment, HER2 testing is mandatory.</p><p>&bull;A To minimise allergic reactions, you will be given other medicines before you receive CANHERA 150 mg Injection. These medicines can&nbsp; be given as either tablets or infusion into a vein or both.</p><p>&bull; <strong>You will receive </strong>CANHERA 150 mg <strong>injection as a drip into one of your veins </strong>(by intravenous</p><p>infusion), through an in-line filter. CANHERA 150 mg Injection will be administered to you by a healthcare professional. He or she will prepare the solution for infusion before it is given to you. Depending on the type and severity of the cancer you will receive CANHERA 150 mg injection either alone or in combination with another anticancer agent. CANHERA 150 mg injection should always</p><p>be administered into one of your veins over a period of 90 minutes. Depending on the type and severity of the cancer, frequency of CANHERA 150 mg can be either every week or every 3 weeks as decided by your doctor.</p><p>&bull; <strong>If the initial loading dose is well -tolerated</strong>, subsequent doses will be administered as a 30- minute infusion. You should be observed for at least six hours after the start of the first infusion and for two hours after the start of subsequent infusions for symptoms like fever and chills or other related reactions. If there are any display of infusion-associated symptoms, the infusion may be interrupted to help control the symptoms; and may be resumed once the symptoms have abated.</p><p>&bull; CANHERA 150 mg will not to be administered as an intravenous push or bolus and will not be mixed with other medications.</p><p>&bull; If you are diagnosed with MBC and MGC then you will be treated with CANHERA 150 mg until disease progression.<br />&bull; Only a physician/doctor experienced in the administration of chemotherapy treatment will be initiating treatment.</p><p>If a dose of CANHERA 150 mg has been missed:</p><p>If you miss a dose greater than a week then you will be administered with a reloading dose of CANHERA 150 mg over approximately 90 minutes followed by subsequent maintenance doses.</p><p>If you stop using CANHERA 150 mg injection</p><p>Do not stop using this medicine without talking to your doctor first. All doses should be taken at the right time every week or every three weeks (depending on your dosing schedule). This helps your medicine work well.</p><p>It may take up to 7 months for CANHERA 150 mg to be removed from your body. Therefore, your doctor may decide to continue to check your heart functions, even after you finish treatment.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, CANHERA 150 mg can cause side effects, although not everybody gets them.</p><p>Some of these side effects may be serious and may lead to hospitalization.</p><p>Tell your doctor immediately if you notice any of the following signs. These may include one or more of the following:</p><p>&bull; Flushing,</p><p>&bull; Skin reactions</p><p>&bull; Chest tightness,</p><p>&bull; Shortness or difficulty in breathing,</p><p>&bull; Palpitations (heart fluttering or irregular heart beat).</p><p>&bull; Swelling or fluid retention in the legs or arms, These can all be signs of serious side effects.</p><p>&bull; If you have ulcers, abscesses (collection of pus),&nbsp; rashes, fever, wounds that a longer time to heal(signs of neutropenia).</p><p>&bull; If you experience flushing, rash, fever, rigors, chills (signs of infusion-related reactions)<br />Occasionally, signs or symptoms start later than six hours after the infusion begins. If this happens to you, contact your doctor immediately. Sometimes, symptoms may improve and then get worse later.Other side effects can occur at any time during treatment with CANHERA, not just related to an infusion. Heart problems can sometimes occur during treatment and occasionally after treatment has stopped and can be serious. They include weakening of the heart muscle possibly leading to heart failure, inflammation (swollen, red, hot, and in pain) of the lining around the heart and heart rhythm disturbances. This can lead to symptoms</p><p>such as:</p><p>- breathlessness (including breathlessness at night),</p><p>- cough,</p><p>- fluid retention (swelling) in the legs or arms,</p><p>- palpitations (heart fluttering or irregular heart beat).</p><p>Your doctor will monitor your heart regularly during and after treatment but you should tell your doctor immediately if you notice any of the above symptoms. The following undesirable effects are categorized on the basis of frequency of occurrence of adverse reactions.</p><p><strong>Very common side effects of </strong>CANHERA 150 mg</p><p><strong>(more than 1 in 10 patients):</strong></p><p>&bull; Tremor,</p><p>&bull; Hair loss (alopecia)</p><p>&bull; Decrease or increase in blood pressure,</p><p>&bull; Irregular heartbeat,</p><p>&bull; Palpitation,</p><p>&bull; lip swelling, swelling face,</p><p>&bull; Tightness of the muscle (adverse reactions reported largely in association with infusion related reactions),</p><p>&bull; wheezing (adverse reactions reported in association with a fatal outcome and infusion related reactions),</p><p>&bull; Difficulty in breathing (adverse reactions reported in association with a fatal outcome),</p><p>&bull; Infections,</p><p>&bull; low grade fever, sore mouth, pain of the gums and swelling, cough (signs of febrile neutropenia),</p><p>&bull; weight decreased/weight loss,</p><p>&bull; weight increased,</p><p>&bull; Difficulty falling asleep,</p><p>&bull; dizziness,</p><p>&bull; Headache,</p><p>&bull; Tingling or pricking sensation (paraesthesia),</p><p>&bull; Reduced sense of touch or sensation(hypoaesthesia),</p><p>&bull; Distortion of taste (dysgeusia),</p><p>&bull; Pinkeye (conjunctivitis),</p><p>&bull; Flow of tears increased,</p><p>&bull; hot flush,</p><p>&bull; cough,</p><p>&bull; Bleeding of the nose (epistaxis),</p><p>&bull; diarrhoea,</p><p>&bull; vomiting,</p><p>&bull; nausea,</p><p>&bull; Pain of the abdomen,</p><p>&bull; Difficulty in emptying bowels (constipation),</p><p>&bull; Sore mouth (stomatitis).</p><p>&bull; Tests may show: reduction of blood platelet count, white or red blood cells count, low blood pressure</p><p><strong>Common side effects </strong>CANHERA 150 mg <strong>(less than 1 in 10 patients):</strong></p><p>&bull; Heart failure,</p><p>&bull; Infection of the lung,</p><p>&bull; Infection of pancreas,</p><p>&bull; Painful breathing and cough. Deep breathing increases the pain (adverse reactions reported in association with a fatal outcome);</p><p>&bull; Light-headedness or dizziness. Palpitations (skipping, fluttering or pounding in the chest) Fatigue (supraventricular tachycardia)</p><p>&bull; Infections of the upper respiratory or urinary track,</p><p>&bull; sinusitis, skin infection, runny nose,</p><p>&bull; anxious, depression, thinking abnormal,</p><p>&bull; dry eye,</p><p>&bull; Joint pain, back pain, bone pain, muscle spasms, neck pain, pain in extremity.</p><p><strong>Uncommon side effects </strong>CANHERA 150 mg <strong>(may effect up to 1 in 100 people):</strong></p><p>&bull; Blood infection,</p><p>&bull; deafness,</p><p>&bull; bumpy rash,</p><p>&bull; abnormal accumulation of fluid around the heart</p><p><strong>Rare side effects </strong>CANHERA 150 mg (may effect up to 1 in 1000 people)</p><p>&bull; weakness,</p><p>&bull; jaundice,</p><p>&bull; inflammation or scarring of the lungs</p><p><strong>Other side effects </strong>that have been reported with CANHERA 150 mg use: frequency cannot be estimated from the available data:</p><p>&bull; abnormal or impaired blood clotting</p><p>&bull; anaphylactic reactions</p><p>&bull; high potassium levels</p><p>&bull; swelling of the brain</p><p>&bull; swelling or bleeding at the back of the eyes</p><p>&bull; shock</p><p>&bull; swelling of the lining of the heart</p><p>&bull; slow heart rate</p><p>&bull; abnormal heart rhythm</p><p>&bull; respiratory distress</p><p>&bull; respiratory failure</p><p>&bull; acute accumulation of fluid in the lungs</p><p>&bull; acute narrowing of the airways</p><p>&bull; abnormally low oxygen levels in the blood</p><p>&bull; difficulty in breathing when lying flat</p><p>&bull; liver damage/failure</p><p>&bull; swelling of the face, lips and throat</p><p>&bull; kidney failure</p><p>&bull; abnormally low levels of fluid around baby in womb</p><p>&bull; failure of the lungs of the baby to develop in the womb</p><p>&bull; abnormal development of the kidneys of the baby in the womb</p><p>If you experience any of the above symptoms when your treatment with CANHERA 150 mg has finished, you should see your doctor and tell them that you have previously been treated with CANHERA 150 mg.</p><p>Some of the side-effects you experience may be due to your underlying cancer. If you receive CANHERA 150 mg in combination with chemotherapy, some of them may also be due to the chemotherapy.</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach of children. Do not use CANHERA 150 mg after the expiry date which is stated on the outer carton and on the vial label. The expiry date refers to the last day of that month.<br />&bull; high potassium levels<br />&bull; failure of the lungs of the baby to develop in the womb<br />&bull; Store in a refrigerator (2&deg;C to 8&deg;C).<br />&bull; Infusion solutions should be used immediately after dilution. Do not use CANHERA 150 mg if you notice any particulate matter or discoloration prior to administration.</p><p>&bull; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no&nbsp;longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a. The active substance is trastuzumab. One vial<br />contains 150 mg of trastuzumab What CANHERA 150 mg contains<br />&bull; The other ingredients&nbsp;is</p><p>L - histidine hydrochloride monohydrate 3.36 mg, L-histidine 2.16 mg, Polyethylene Glycol 3350 (Macrogol 3350) 33.6 mg, D-Sorbitol 115.2 mg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                CANHERA 150 mg is a powder for concentrate for solution for intravenous infusion, which is supplied in a glass vial with a rubber stopper containing 150 mg of trastuzumab. The powder is a white to pale yellow pellet. 
Each carton contains 1 vial of powder.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MANUFACTURED BY<br />Biocon Limited<br />Special Economic Zone<br />Bommasandra-Jigani Link Road,<br />Bommasandra Post,<br />Bengaluru-560 099</p><p>MARKETED BY<br />16 Great Queen Street<br />London<br />WC2B 5AH<br />United Kingdom<br />Biocon House, Semicon Park, Electronics City Phase II,<br />Biocon Biologics Limited<br />Bengaluru&ndash;560100.<br />Telephone: +91-80-6775 1107<br />For any information about this medicinal product, please<br />contact the local representative of the Marketing<br />Authorisation Holder: Medical Advisor<br />Leaflet generated November 2017<br />Covent Garden</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                d. This leaflet was last approved in {03/2020};

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="ltr">ملغ 150 وما هي استخداماته: CANHERA 2. ما هو ال<br />150 ملغ الجرعة الواحدة، تحتوى على مسحوق مركز عن , ملغ 150 CANHERA اسم دواءك هو<br />.&quot; ملغ 150 CANHERA &quot; طريق الحقن في الوريد ولكن خلال بقية النشرة نطلق علية اسم<br />:مجموعة العلاج الدوائي<br />ينتمى الى مجموعة الادوية المضادة للسرطان تسمى اجسام مضادة CANHERA 150 ملغ<br />وهي من صنع الانسان عن طريق الاستنساخ الجزيئي للأجسام باستخدام ( monoclonal antibodies)<br />و بالتالي عرقلة و وقف نمو HER تكنولوجيا الحمض الخلوي الصبغي ويعمل على منع المستقبلات 2<br />السرطان.<br />ملغ 150 المستخدمة تتم لمعالجة ما يلي: CANHERA جرعة<br />.( HER &bull; سرطان الثدى المبكر بمستويات عالية من بروتين ( 2<br />,HER &bull; سرطان الثدي النقلي ( سرطان الثدي الذي انتشر خارج الورم الأصلي ) بمستويات عالية من 2<br />او عقار paclitaxel عادة يوصف بالاقتران و الاتصال مع العلاج الكيميائي مثل CANHERA 150 ملغ<br />دوستاكسيل كأول علاج لسرطان الثدى النقيلي او يوصف لوحدها اذا كانت العلاجات الاخرى اثبتت فشلها.<br />مع المرضى الذين عندهم مستويات عالية من aromatase Inhibitors كما تستخدم بالارتباط مع الادوية<br />ومستقبلات الهرمون الموجبة لسرطان الثدي النقلي HER2<br />(السرطان الذي يكون حساسا لوجود الهرمونات الانثوية)<br />( HER &bull; سرطان المعدة النقلي، سرطان المعدة الذي انتشر خارج الورم الأصلي ( بمستويات عالية من 2<br />.5-flououracil cisplatin او ,capecitabine : عند اقترانه مع أدوية السرطان الاخرى مثل<br />&bull; يخضع هذا الدواء للوصفة الطبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr"><strong>: ملغ 150 CANHERA 3. قبل استخدام ال</strong></p><p dir="ltr"><strong>ملغ 150 إذا</strong><strong>: CANHERA أ. لا تستخدم ال</strong></p><p dir="ltr">إذا كان هناك حساسية من التراستوزوماب أو بروتينات المادة العلمية او الى اى من المكونات الاخرى&bull;</p><p dir="ltr">المدرجة من هذا الدواء في المادة. 6</p><p dir="ltr">عسر تنفس الحاد) عند الاستلقاء بسبب مضاعفات عامة أو شقيقة متقدمة وتتطلب ) dyspnoea &bull; لديك</p><p dir="ltr">استخدام العلاج بالأوكسجين التكميلي.</p><p dir="ltr">&nbsp; إذا كنتي من الحوامل او المرضعات لطفلك&bull;</p><p dir="ltr"><strong>ملغ إذا واجهتك اية من الاعراض المذكورة ادناه فان</strong><strong> CANHERA ب. احرص بشكل خاص مع 150</strong></p><p dir="ltr"><strong>الانذار المبكر والتدابير الوقائية لازمة</strong>.</p><p dir="ltr"><strong>:ج. التحذيرات والاحتياطات</strong></p><p dir="ltr">ينبغى البدء فى العلاج الخاص بك تحت اشراف الطبيب الذي يجب ان يكون ذا خبرة فى علاج السرطان</p><p dir="ltr">لأنه فى الحالات التالية يمكن ان يحدث ما يلي :</p><p dir="ltr">اذا واجهت (ضيق فى التنفس او صعوبة في التنفس، وخاصة عند المجهود الجسدي أو الرياضي أو&bull;</p><p dir="ltr">الارهاق أو تورم وانتفاخ في الكاحل او القدمين والرجلين والبطن أو أن الاوردة تعرضت لجلطة)</p><p dir="ltr">CARDIOMYOPATHY</p><p dir="ltr">إذا واجهت (احمرار أو الحمى والطفح الجلدي وقسوة أو القشعريرة ) كلها علامات تفاعلات الحقن&bull;</p><p dir="ltr">الوريدية.</p><p dir="ltr">إذا واجهت انقطاع النفس اثناء ممارسة الرياضة أو جفاف الحلق (هذه علامات السمية الرئوية) &bull;</p><p dir="ltr">عدد كرات الدم ) ) NEUTROPHILE اذا تفاقم العلاج الكيماوي بسبب انخفاض مستوى &bull;</p><p dir="ltr"><strong>:د. فحوصات القلب</strong></p><p dir="ltr">قد تؤثر على القلب وخاصة اذا كنت قد taxane ملغ 150 بمفردة أو مع CANHERA العلاج ب</p><p dir="ltr">و هما نوعان اخران من الادوية anthracyclines (taxanes AND anthracycline ) استخدمت</p><p dir="ltr">المستخدمة لعلاج السرطان.</p><p dir="ltr">التأثيرات قد تكون شديدة او متوسطة، وقد تتسبب في الوفاة. لذلك، سيتم فحص وظائف القلب قبل</p><p dir="ltr">ملغ . 150 CANHERA واثناء (كل ثلاثة شهور) وبعد حتى (سنتين الى خمس سنوات) عند العلاج ب</p><p dir="ltr">اذا: CANHERA 150 mg تحدث الى طبيب او ممرضة أو صيدلى قبل اعطاء</p><p dir="ltr">&bull; اخذت الادوية المتصلة بظروف القلب مثل ارتفاع ضغط الدم.</p><p dir="ltr">وهو من الادوية (epirubicin OR doxorubicin) &bull; إذا أخذت في الماضي او استخدمت دواء</p><p dir="ltr">تؤدي الى تلف عضلة القلب وزيادة خطر (anthracyclines) المستخدمة لعلاج السرطان، هذه الادوية</p><p dir="ltr">CANHERA . مشاكل القلب مع 150 ملغ</p><p dir="ltr">CANHERA ال 150 ملغ .taxane , &bull; اذا كنت تعانى من انقطاع النفس، خاصة اذا كنت تستخدم حاليا</p><p dir="ltr">قد يسبب ضيق في التنفس، خصوصا عندما تكون في البداية، وهذا يمكن ان يكون أكثر خطورة إذا كنت</p><p dir="ltr">ممن يعانون من ضيق في التنفس أصلا، ومن النادر جدا ان المرضى الذين يعانون من صعوبات شديدة</p><p dir="ltr">. ملغ 150 CANHERA في التنفس يلقوا مصرعهم عند اعطائهم</p><p dir="ltr">&bull; إذا حصلت على أي علاج لسرطان.</p><p dir="ltr">ملغ 150 مع أي دواء لعلاج السرطان مثل: CANHERA إذا تلقيت</p><p dir="ltr">paclitaxel, aromatase Inhibitor, docetaxel, 5-fluorouracil, capecitabine، cisplatin</p><p dir="ltr">يتعين عليك ايضا قراءة معلومات المرضى في النشرة الداخلية لهذه المنتجات.</p><p dir="ltr"><strong>:الاطفال والمراهقين</strong></p><p dir="ltr">غير موصى به لأي شخص يقل عمره عن 18 سنة. CANHERA 150 ملغ</p><p dir="ltr">: ملغ 150 CANHERA الادوية الاخرى و</p><p dir="ltr">أخبر الطبيب او الممرضة أو الصيدلي إذا كنت او أنك حاليا تأخذ أي ادوية اخرى.</p><p dir="ltr">ملغ 150 في الجسم. ولذلك يجب عليك اخبار CANHERA قد يستغرق ما يصل الى 7 أشهر للتخلص من</p><p dir="ltr">ملغ 150 في حال بدء أي دواء جديد CANHERA الطبيب او الممرضة أو الصيدلي بانه تم أخذ دواء ال</p><p dir="ltr">. ملغ 150 CANHERA فى 7 اشهر بعد توقف العلاج ب</p><p dir="ltr"><strong>:الحمل</strong></p><p dir="ltr">&bull; إذا كنتي حاملا، أو هل تظني بانك قد تكوني حاملا او تخططون لإنجاب طفل، اسال الدكتور أو صيدلى</p><p dir="ltr">او ممرضة للحصول على المشورة قبل اتخاذ هذا الدواء.</p><p dir="ltr">ملغ 150 على الاقل 7 أشهر بعد CANHERA &bull; ينبغي عليك استخدام وسائل منع الحمل اثناء العلاج ب</p><p dir="ltr">انتهاء العلاج.</p><p dir="ltr">اثناء الحمل، وفى CANHERA &bull; طبيبك سينصحك بالمخاطر والمنافع التي تحدث عند أخذ 150 ملغ</p><p dir="ltr">حالات نادرة يحدث انخفاض بالسائل الذي يحيط بالطفل داخل الرحم عند الحوامل الاتي يأخذن ال</p><p dir="ltr">مليجرام وهذه الظروف قد تكون مضرة للطفل في الرحم وهذا ما يسبب عدم تطور CANHERA 150</p><p dir="ltr">رئة الجنين في الرحم الام وبالتالي يؤدي الى موت الجنين.</p><p dir="ltr"><strong>:الرضاعة الطبيعية</strong></p><p dir="ltr">ملغ وذلك لمدة 7 أشهر بعد اخر جرعة من CANHERA لا ترضعي طفلك أثناء العلاج بال 150</p><p dir="ltr">ملغ 150 قد تمر لطفلك عبر حليب الثدي. CANHERA ، ملغ 150 CANHERA</p><p dir="ltr">اسال الطبيب او الصيدلى للحصول على المشورة قبل اتخاذ اى دواء.</p><p dir="ltr"><strong>:القيادة واستخدام الالات</strong></p><p dir="ltr">على قدرتك على قيادة السيارة او تشغيل الآلات. CANHERA لا يعرف ما إذا كان يمكن ان يؤثر 150 ملغ</p><p dir="ltr">ولكن إذا واجهتك اثناء العلاج اعراض مثل الحمى او برودة ينبغى الا تقود او تستخدم الماكينات حتى تختفي</p><p dir="ltr">هذه الاعراض</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr"><strong>:Biocon ملغ 150 من شركة CANHERA 4. كيفية أخذ الدواء</strong></p><p dir="ltr">ملغ 150 سوف يحدد لك من قبل طبيك من ذوى الخبرة في علاج السرطان. CANHERA</p><p dir="ltr">الزامى. HER فان اختبار 2 trastuzumab قبل البدء بتلقى العلاج ب</p><p dir="ltr">: التقليل الى الحد الادنى من التفاعلات الحساسية&bull;</p><p dir="ltr">ملغ حقن و يمكن ايضا اعطاء هذه الادوية CANHERA سيتم منحك ادوية اخرى قبل العلاج ب 150</p><p dir="ltr">اما عن طريق اقراص او حقن في الوريد او كليهما</p><p dir="ltr">ملغ 150 حقن في التقطير خلال أحد شرايين (عن طريق الحقن الوريدى) أو من CANHERA &nbsp;&nbsp;ستتلقى&bull;</p><p dir="ltr">حقن ستعطى لكم عن طريق أشخاص مأهلين صحين CANHERA خلال حقن المحلول 150 , ملغ</p><p dir="ltr">متخصصين في هذا المجال. هو أو هي سيقوم بتحضير الحقن قبل ان تعطى لك. تبعا لنوع وشدة السرطان</p><p dir="ltr">ملغ أما حقن منفردة او بالاضافة الى أدوية سرطان أخرى، CANHERA ستتلقى جرعة 150</p><p dir="ltr">حقن ينبغى دائما ان تعطى في أحد شرايين على مدى 90 دقيقة. تبعا لنوع وشدة CANHERA 150 ملغ</p><p dir="ltr">ملغ 150 اما ان تكون كل اسبوع او كل 3 اسابيع حسب ما يقرره الطبيب. CANHERA ، ونوع السرطان</p><p dir="ltr">إذا ما تم اعطاء الجرعة الأولى بطريقة صحيحة وتم احتمالها، فان الجرعات المتلاحقة تأخذ كل 30 دقيقة&bull;</p><p dir="ltr">في شكل جرعة واحدة، ويجب ان تتم الملاحظتة على الاقل لمدة ست ساعات من بدء اولى الحقن والملاحظة</p><p dir="ltr">لمدة ساعتين من بدء الجرعات اللاحقة لملاحظة الاعراض مثل الحمى، برودة او غيره من ردود الفعل</p><p dir="ltr">إذا كان هناك أي عرض من اعراض مرتبطة الحقن، فان الحقن يتم وقفها وذلك للمساعدة فى السيطرة على&bull;</p><p dir="ltr">الاعراض الجانبية ويمكن استئناف الحقنة في حال أن الاعراض قد خفت</p><p dir="ltr">أو أن تكون مختلطة مع intravenous push or bolus لا يعطى عن طريق CANHERA 150 ملغ &bull;</p><p dir="ltr">ادوية الاخرى</p><p dir="ltr">الى أن يتم CANHERA سيتم العلاج ب 150 ملغ MGC أو MBC &nbsp;إذا تم تشخيصك بالإصابة ب ال&bull;</p><p dir="ltr">اظهار نتائج ايجابية من المرض</p><p dir="ltr">الطبيب/ أو الطبيب ذو الخبرة فى اعطاء العلاج الكيماوي سيكون البادئ بالعلاج&bull;</p><p dir="ltr"><strong>ملغ 150 CANHERA إذا تخطى جرعة الدواء</strong></p><p dir="ltr">لمدة حوالي CANHERA 150 mg إذا تم تخطي الجرعة أكثر من اسبوع، فسوف يعطى المريض جرعة</p><p dir="ltr">90 دقيقة بعد ذلك يتبعها جرعة محافظة</p><p dir="ltr"><strong>ملغ 150 CANHERA إذا قمت بإيقاف استخدام حقن</strong></p><p dir="ltr">لا تقوم بوقف استخدام هذا الدواء دون التحدث الى طبيبك اولا. وينبغى ان تؤخذ جميع الجرعات في الوقت</p><p dir="ltr">المناسب (كل اسبوع او كل ثلاثة اسابيع) حسب الجدول الزمنى للجرعية وهذا يساعد على جعل دوائك يعمل</p><p dir="ltr">بشكل جيد</p><p dir="ltr">ملغ 150 للخروج من جسمك. وذلك يقررة طبيبك بعد CANHERA قد يستغرق ما يصل الى 7 اشهر ل</p><p dir="ltr">مواصلة التحقق من وظائف القلب، حتى بعد الانتهاء من العلاج</p><p dir="ltr">إذا كان لديك المزيد من الاسئلة المتعلقة باستخدام هذا الدواء، اسأل دكتور الصيدلي أو ممرضة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>5. </strong><strong>اثار جانبية محتملة</strong><strong>:</strong></p><p>ملغ 150 يسبب أعراضا جانبية، ولكنها ليست للكل، البعض من هذه الاثار CANHERA مثل كل الادوية</p><p dir="RTL">الجانبية قد تكون خطيرة وقد تؤدى بك الى المستشفى</p><p dir="RTL">أخبر طبيبك فورا إذا لاحظت أي من العلامات التالية. وهذه قد تشمل واحدا او أكثر مما يلي:</p><p dir="RTL">&bull; احمرار</p><p dir="RTL">&bull; ردود فعل في الجلد</p><p dir="RTL">&bull; ضيق في الصدر</p><p dir="RTL">&bull; ضيق او صعوبة في التنفس</p><p dir="RTL">&bull; تورم او تجمع السوائل في سيقان او الاذرع،</p><p dir="RTL">&bull; (رفرفة القلب والخفقان) او عدم انتظام ضربات القلب.</p><p dir="RTL">جميعها علامات من أثار جانبية خطيرة.</p><p dir="RTL">أخبر الطبيب فورا:</p><p dir="RTL">&bull; إذا كان لديك قرحة أو الخراجات (تجمع صديد) والطفح الجلدي، أو الحمى أو الجروح تأخذ مدة أطول</p><p dir="RTL">(neutropenia ) في الالتئام كلها علامات ال</p><p dir="RTL">&bull; إذا واجهت (احمرار، الحمى والطفح الجلدي وقشعريرة والتبرد (علامات ردود الفعل المتصلة بالحقن.</p><p dir="RTL">وأحيانا توجد اعراض تبدأ في وقت لاحق من ست ساعات بعد بداية الحقن. إذا حدث ذلك، استشر طبيبك</p><p dir="RTL">على الفور. وفى بعض الاحيان، قد تتحسن الأعراض ثم تزداد سوءا فى وقت لاحق.</p><p dir="RTL">ملغ 150 ليس CANHERA والاثار الجانبية الاخرى يمكن ان تحدث في أي وقت خلال فترة العلاج مع</p><p dir="RTL">فقط في الحقن.</p><p dir="RTL">مشاكل فى القلب يمكن ان تحدث احيانا اثناء العلاج وأحيانا بعد توقف العلاج ويمكن أن تكون خطيرة.</p><p dir="RTL">وهي تشمل ضعف عضلة القلب قد يؤدى الى قصور القلب، والتهاب (منتفخة، حمراء، دافئة، الالم) في</p><p dir="RTL">البطانة حول القلب والى اضطرابات في نبضات القلب. وهذا يمكن ان يؤدى الى اعراض مثل:</p><p dir="RTL">&bull; انقطاع النفس (بما فى ذلك انقطاع النفس اثناء الليل)</p><p dir="RTL">&bull; السعال</p><p dir="RTL">&bull; تجمع السوائل (تورم) فى السيقان او الاذرع</p><p dir="RTL">&bull; رفرفة في القلب وخفقان (او عدم انتظام ضربات القلب)</p><p dir="RTL">طبيبك سيقوم بمراقبة قلبك بانتظام اثناء وبعد العلاج ولكن يجب عليك اخبار الطبيب فورا إذا لاحظت</p><p dir="RTL">أي من الاعراض.</p><p dir="RTL">فيما يلي الاثار غير المرغوب فيها مصنفة على اساس مدى تواتر حدوثها وردود الفعل معاكسة.</p><p dir="ltr"><strong>ملغ 150 (أكثر من 1 من كل 10 مرضى)</strong><strong>: CANHERA الاثار الجانبية الشائعة جدا</strong></p><p dir="ltr">&bull; رعشة</p><p dir="RTL">&bull; تساقط الشعر (الصلع)</p><p dir="RTL">&bull; الزيادة او النقصان فى ضغط الدم</p><p dir="RTL">&bull; عدم انتظام ضربات القلب</p><p dir="RTL">&bull; خفقان القلب</p><p dir="RTL">&bull; انتفاخ الشفاه وانتفاخ فى الوجه</p><p dir="RTL">&bull; تضيق العضلات (ردود الفعل السلبية الى حد كبير مع ردود الفعل المتعلقة بالحقن)</p><p dir="RTL">&bull; الحشرجة (ردود فعل سلبية مع نتائج قاتلة وردود الفعل المتعلقة بالحقن)</p><p dir="RTL">&bull; صعوبة فى التنفس (ردود الفعل السلبية فى الاقتران نتيجة مهلكة)</p><p dir="RTL">&bull; التهابات</p><p dir="RTL">(neutropenia) &bull; درجة منخفضة من الحمى والتهاب الفم، الم اللثة، وتورم والسعال</p><p dir="RTL">&bull; انخفاض الوزن/فقدان الوزن</p><p dir="RTL">&bull; زيادة الوزن</p><p dir="RTL">&bull; صعوبة فى النوم</p><p dir="RTL">&bull; الدوار</p><p dir="RTL">&bull; الصداع</p><p dir="RTL">(paraesthesia ) &bull; واحساس بالوخز او الاحساس وخزه كدبابيس</p><p dir="RTL">(hypoaesthesia) &bull; انخفاض حاسة اللمس او الاحساس</p><p dir="RTL">( dysgeusia ) &bull; فقدان حاسة التذوق</p><p dir="RTL">(Pinkeye) &bull; الملتحمة</p><p dir="RTL">&bull; زيادة تدفق الدموع</p><p dir="RTL">&bull; احمرار</p><p dir="RTL">&bull; السعال</p><p dir="RTL">(epistaxis) &bull; نزيف الانف</p><p dir="RTL">&bull; الاسهال</p><p dir="RTL">&bull; التقيؤ</p><p dir="RTL">&bull; الغثيان</p><p dir="RTL">&bull; الم البطن</p><p dir="RTL">&bull; صعوبة فى افراغ الامعاء (الامساك)</p><p dir="RTL">&bull; قرحة الفم (التهاب الفم)</p><p dir="RTL">&bull; الاختبارات قد تظهر: تخفيض عدد صفائح الدموية وعدد خلايا الدم البيضاء او خلايا الدم الحمراء،</p><p dir="RTL">وانخفاض في ضغط الدم.</p><p dir="ltr"><strong>ملغ 150 (اقل من 1 من كل 10 مريضا)</strong><strong> : CANHERA الاثار الجانبية المشتركة</strong></p><p dir="ltr">&bull; السكتة القلبية</p><p dir="RTL">&bull; عدوى الرئة.</p><p dir="RTL">&bull; اصابة البنكرياس.</p><p dir="RTL">&bull; ألام عند التنفس وسعال، التنفس العميق يزيد الالم (ردود الفعل السلبية فى الاقتران نتيجة مهلكة)</p><p dir="RTL">&bull; عدم والاتزان او الدوار. والخفقان (التخطي، ترفرف في صدر) الاجهاد</p><p dir="RTL">(superventricukar tachycardia)</p><p dir="RTL">&bull; التهابات في المجاري التنفسية العليا او والمسالك البولية</p><p dir="RTL">&bull; اصابات الجلد والرشح والعطاس</p><p dir="RTL">&bull; قلق والاكتئاب والتفكير الغير طبيعي</p><p dir="RTL">&bull; جفاف العين</p><p dir="RTL">&bull; الام المفاصل، الام الظهر، الام العظام والعضلات، الم الرقبة والام فى الانارة.</p><p dir="ltr"><strong>شخص): &nbsp;&nbsp;</strong><strong>100 &nbsp;ملغ 150 (قد يؤثر على ما يصل الى1 - CANHERA الاثار الجانبية غير مالوفة</strong></p><p dir="ltr">&bull; التهابات الدم</p><p dir="RTL">&bull; الصمم</p><p dir="RTL">&bull; طفح وعر والطفح الجلدى</p><p dir="RTL">&bull; تجمع غير طبيعى للسوائل حول القلب</p><p dir="ltr"><strong>:( ملغ (قد يؤثر على ما يصل الى 1 في 1000 CANHERA الاثار الجانبية النادرة ل 150</strong></p><p dir="ltr">&bull; ضعف.</p><p dir="RTL">&bull; اليرقان</p><p dir="RTL">&bull; التهاب او ندبات في الرئتين</p><p dir="ltr"><strong>ملغ 150 : بسبب التكرار</strong><strong> CANHERA والاثار الجانبية الاخرى التي ابلغت عنها مع الدواء ب</strong></p><p dir="ltr"><strong>لا يمكن احصاء تقديرها من البيانات المتاحة</strong><strong>:</strong></p><p dir="RTL">&bull; تخثر الدم الغير طبيعى او مزدوج</p><p dir="RTL">anaphylactic &bull; ردود فعل</p><p dir="RTL">&bull; ارتفاع مستويات البوتاسيوم</p><p dir="RTL">&bull; تورم فى المخ</p><p dir="RTL">&bull; تورم او نزيف فى عيون<br />&bull; صدمة<br />&bull; تضخم بطانة القلب<br />&bull; بطء معدل ضربات القلب<br />&bull; انتظام ضربات قلب غير طبيعي<br />&bull; ضيق التنفس<br />&bull; فشل في التنفس<br />&bull; مرض تراكم السائل فى الرئتين<br />&bull; مرض تضييق في المجاري الهوائية<br />&bull; انخفاض نسبة الاكسجين فى الدم بشكل غير طبيعى<br />&bull; صعوبة فى التنفس عندما يستلقون<br />&bull; فشل الكبدي<br />&bull; تورم فى الوجه والشفاه والحنجرة<br />&bull; فشل كلوي<br />&bull; انخفاض مستويات السائل حول الطفل فى الرحم بكمية غير عادية<br />&bull; فشل تطور رئة الجنين فى الرحم<br />&bull; تطور غير عادى في كلى الجنين في الرحم</p><p dir="ltr">ملغ 150 بعد انتهاء العلاج فيجب CANHERA إذا واجهت أي من الاعراض السابقة مع<br />ملغ 150 CANHERA الرجوع الى طبيب واخباره بانك سبق لك استعمال<br />بعض الاثار الجانبية التي تحصل معك بسبب الاصابة الكامنة بالسرطان أو إذا تلقيت<br />ملغ 150 مع العلاج الكيميائي، أو بعضها قد يكون ايضا بسبب العلاج الكيميائي. CANHERA<br />إذا كانت أي من الاثار الجانبية أصبحت جادة، أو إذا لاحظت أي اثار جانبية غير مدرجة فى<br />هذه النشرة، فيرجى اعلام طبيبك، صيدلى او ممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">: ملغ 150 CANHERA 6. كيفية تخزين<br />&bull; يبقى هذا الدواء بعيدا من متناول الاطفال.<br />&bull; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية على العبوة الخارجى وعلى ملصق الزجاجة.<br />تاريخ انتهاء الصلاحية يشير الى اخر يوم من الشهر نفسه.<br />&bull; يحفظ في ثلاجة ما بين ( 2 درجة مئوية الى 8 درجة مئوية) .<br />ملغ 150 إذا لاحظت CANHERA &bull; يجب استخدام محلول حقن فورا بعد التخفيف. لا تستخدم<br />أي الجسيمات او تغير في اللون قبل الاستعمال.<br />&bull; الادوية يجب عدم التخلص منها في النفايات المنزلية أو عبر المياه المستعملة. اسال الصيدلى<br />عن كيفية التخلص من الادوية التي لم تعد مطلوبة. ومن شان هذه التدابير ان تساعد فى حماية<br />البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">حتوي: CANHERA على ماذا 150 ملغ .A<br />(vial) جرعة واحدة باستخدام mg 150<br />يتعين حله trastuzumab كل حقنة تحتوي على 150 ملغ trastuzumab &bull; المادة النشطة هي<br />في 7.2 ملل من الماء.<br />والعناصر الاخرى مثل: .trastuzumab &bull; يحتوي المحلول الناتج حوالي 21 ملليغرام/ملليلتر<br />L-histidine hydrochloride monohydrate 3.36 mg<br />L- histidine 2.16 mg<br />polyethylene Glycol 3350 (macrogel 3350) 33.6 mg<br />D- Sorbitol 115 mg<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">ومحتويات العلبة: CANHERA كيف يبدو 150 ملغ .B<br />هو بودرة محلول مركزة لحقن وريدية عن طريق الحقن فى الوريد، CANHERA 150 ملغ<br />ملغ من trastuzumab و هي محفوظة في فيال زجاجي مع سدادة مطاطية تحتوي على 150<br />مسحوق ابيض مائل الى اللون الاصفر الباهت. كل كرتونة تحتوي على مسحوق في فيال<br />زجاجي واحد فقط.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">امل ترخيص التسويق والشركات المصنعة: .C<br />صنع هذا المنتج عن طريق:<br />Biocon Limited<br />Special economic zone<br />Plot No. 2, 3, 4 &amp; 5, phase IV<br />Bommasandra-Jigani Link Road<br />Bommasandra Post<br />Bangalore-560 099<br />India<br />تسويق هذا المنتج عن طريق:<br />Biocon biologics limited<br />Great Queen Street 16<br />Covent Garden<br />London<br />WC2B 5AH<br />UNITED Kingdom<br />لمزيد من معلومات والتفاصيل حول هذا المنتج الطبي، يرجى الاتصال بالممثل المحلي لحامل<br />تصريح التسويق:<br />مستشارنا الطبي:<br />Biocon House, Semicon Park, Electronic City Phase II<br />بانجالور 560100<br />+91-80-6775- الهاتف: 1107<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رقم الاصدار: ; {03/2020} هذا المنشور في الماضي 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CANHERA

GENERIC NAME
Trastuzumab  lyophilized  powder   for  injection   (r-DNA
origin
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                150  mg  single-dose, 150  mg  multi-dose  and 440  mg multi-dose  vials containing powder  for  concentrate  for solution  for   intravenous infusion.  Reconstituted
CANHERA"  concentrate contains approximately 21 mg/mL of trastuzumab, a humanised lgG1 monoclonal antibody expressed in Chinese hamster  ovary cell suspension culture, and purified  by affinity and ion­ exchange chromatography  including  specific   viral inactivation and removal procedures.
Composition of Trastuzumab for Injection
(150 mg I vial)
Component                     Quantity I vial
Trastuzumab 	 150 mg L-Histidine 	2.16 mg L-Histidine Hydrochloride           3.36 mg
Polyethylene Glycol3350 (Macrogol3350) 33.6 mg
D-Sorbitol                                  115.2 mg

Composition of Trastuzumab for Injection (440 mg I
vial)
Component                        Quantity/vial
Trastuzumab 	440 mg L-Histidine 	 6.3 mg L-Histidine Hydrochloride            9.9 mg
Polyethylene Glycol3350 (Macrogol3350) 98.6 mg
D-Sorbitol                                  337.9 mg

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Metastatic Breast Cancer</p><p>CANHERA&quot; &nbsp;is &nbsp;indicated &nbsp;for &nbsp;the&nbsp; &nbsp;treatment &nbsp;of &nbsp;MBC</p><p>patients who have human epidermal growth factor receptor 2- (HER2)-overexpressing tumours.</p><p>Early Breast Cancer (EBC)</p><p>CANHERA&quot; is indicated for &nbsp;the &nbsp;treatment of &nbsp;adult patients with HER2 positive EBC.</p><p>CANHERA&quot;should only be used in MBC or EBC patients who have tumours with either overexpression of HER2 or HER2 gene amplification.</p><p>Metastatic Gastric Cancer (MGC)</p><p>CANHERA&quot; in &nbsp;combination with &nbsp;capecitabine&nbsp; &nbsp;or &nbsp;5- fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who &nbsp;have not &nbsp;received &nbsp;prior &nbsp;anti-cancer treatment for their metastatic disease.</p><p>CANHERA&quot;should &nbsp;be used in only those MGC patients whose tumours overexpress HER2,as defined by:</p><p>&bull; IHC2+ plus &nbsp;a confirmatory silver in situ hybridisation (SISH) or fluorescence in situ hybridisation (FISH) result,OR</p><p>&bull; &nbsp;IHC 3+ result</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before starting trastuzumab treatment. HER2 testing is mandatory.</p><p>&bull; Administertrastuzumab as intravenous infusion.</p><p>&bull; Trastuzumab is not to be administered as an intravenous push or bolus.</p><p>&bull; &nbsp;Do not mix with other drugs.</p><p>&bull; &nbsp;Patients with &nbsp;MBC and MGC should be treated until disease progression.</p><p>&bull; &nbsp;Only a &nbsp;physician experienced in the administration of &nbsp;cytotoxic chemotherapy treatment should &nbsp;initiate treatment. Only a healthcare professional should administer trastuzumab &nbsp;and it should be administered by a healthcare &nbsp;professional prepared &nbsp;to &nbsp;manage anaphylaxis and an emergency kit should be available&nbsp; to &nbsp;manage any&nbsp; &nbsp;unexpected complications.</p><p>&bull; &nbsp;Loading &nbsp;dose should &nbsp;be administered &nbsp;as a 90- minute intravenous infusion. If the initial loading dose is well tolerated, subsequent doses can be administered &nbsp;as a 30-minute infusion. &nbsp;Observe patients for at least six hours after the start of the first infusion and for two &nbsp;hours after the start of subsequent infusions for symptoms like fever and chills or other infusion-related symptoms (see Undesirable Effects). If&nbsp; a patient displays infusion-associated symptoms, the infusion may be interrupted to help control the symptoms;and may be resumed once the symptoms have abated.</p><p>Metastatic Breast Cancer</p><p><em>3-weeklydosing</em></p><p>&bull; An&nbsp; &nbsp;initial &nbsp;loading dose of &nbsp;8 &nbsp;mg/kg &nbsp;is recommended;a maintenance dose of 6 mg/kg at</p><p>3-weekly &nbsp;intervals is recommended, beginning &nbsp;3 weeks after the loading dose.</p><p>&bull; The loading &nbsp;dose should be administered as an intravenous infusion over &nbsp;approximately 90 minutes. The &nbsp;subsequent doses &nbsp;can &nbsp;be administered as a 30-minute infusion, if the initial loading dose was well tolerated.</p><p><em>Weekly dosing</em></p><p>&bull; An&nbsp; &nbsp;initial &nbsp;loading dose of &nbsp;4 &nbsp;mg/kg &nbsp;is recommended;a maintenance dose of 2 mg/kg at weekly intervals is recommended, beginning &nbsp;one</p><p>&nbsp;</p><p>week after the loading dose.</p><p>&bull; The loading &nbsp;dose should be administered as an intravenous infusion <em>over </em>approximately 90 minutes. The &nbsp;subsequent doses can &nbsp;be administered as a 30-minute infusion, if the initial loading dose was well tolerated.</p><p>Trastuzumab is indicated &nbsp;as monotherapy in &nbsp;patients who have already had two &nbsp;or more chemotherapy regimens for metastatic disease. Prior chemotherapy must have been an anthracycline and a taxane (at least), unless patients &nbsp;are unsuitable &nbsp;for these treatments. Hormonal therapy must also have been tried, and have failed, in hormone receptor-positive patients (unless patients are unsuitable for hormonal therapy).</p><p>Trastuzumab is indicated in combination with &nbsp;paclitaxel in patients &nbsp;who &nbsp;have not &nbsp;received chemotherapy &nbsp;for their metastatic disease and for whom an anthracycline is not suitable; in combination with &nbsp;docetaxel in patients who have &nbsp;not &nbsp;received chemotherapy for &nbsp;their metastatic disease; and &nbsp;in combination with an aromatase inhibitor &nbsp;in postmenopausal patients with hormone-receptor positive MBC, who &nbsp;have not previously been treated with trastuzumab.</p><p><em>Administration </em><em>in combination with paclitaxel or docetaxel</em></p><p>In clinical trials, paclitaxel or docetaxel was administered the &nbsp;day following the &nbsp;first &nbsp;dose of trastuzumab (reference product). &nbsp;If the dose was well tolerated, paclitaxeVdocetaxel was administered immediately after the subsequent doses of trastuzumab (reference product).</p><p><em>Administration </em><em>in combination with an aromatase inhibitor</em></p><p>In a clinical trial, trastuzumab &nbsp;(reference product) &nbsp;and anastrozole were administered from day 1; without restrictions on the &nbsp;relative timing &nbsp;of &nbsp;administration of trastuzumab (reference product) and anastrozole.</p><p>Early Breast &nbsp;Cancer</p><p><em>Weekly dosing</em></p><p>Initialloading dose of 4 mglkg followed by 2 mg/kg every week concomitantly with &nbsp;paclitaxel following chemotherapy with doxorubicin and cyclophosphamide. <em>Three-weekly</em><em> </em><em>dosing</em></p><p>An initial &nbsp;loading &nbsp;dose of 8 mg/kg &nbsp;is recommended; &nbsp;a maintenance &nbsp;dose of &nbsp;6 mglkg at 3-weekly &nbsp;intervals is recommended, &nbsp;beginning&nbsp; &nbsp;3 &nbsp;weeks &nbsp;after &nbsp;the &nbsp;loading dose.</p><p>Trastuzumab is indicated &nbsp;after &nbsp;surgery, neoadjuvant &nbsp;or adjuvant chemotherapy,and (if applicable) radiotherapy. Trastuzumab should &nbsp;be&nbsp; &nbsp;used after &nbsp;adjuvant</p><p>chemotherapy with doxorubicin and cyclophosphamide,</p><p>in combination with paclitaxel or docetaxel.</p><p>Trastuzumab should &nbsp;be used in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.</p><p>Trastuzumab should &nbsp;be used in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy, &nbsp;for locally advanced &nbsp;disease (including inflammatory disease) or tumours of diameter</p><p>&gt;2cm.</p><p>Metastatic Gastric Cancer</p><p><em>Three-weekly dosing</em></p><p>An initial &nbsp;loading &nbsp;dose of 8 mg/kg &nbsp;is recommended; &nbsp;a maintenance &nbsp;dose of &nbsp;6 mglkg at 3-weekly &nbsp;intervals is recommended, &nbsp;beginning &nbsp;3 &nbsp;weeks &nbsp;after &nbsp;the &nbsp;loading dose.</p><p>Duration of Treatment</p><p>Patients with &nbsp;MBC or MGC should be treated with trastuzumab until disease progression. Patients with EBC should be treated with &nbsp;trastuzumab &nbsp;for &nbsp;1 year or until disease recurrence, whichever &nbsp;occurs first; &nbsp;it is not recommended &nbsp;to extend treatment in EBC beyond one year.</p><p>Dose Reduction</p><p>During periods of reversible chemotherapy-induced myelosuppression, trastuzumab &nbsp;may be continued; but observe &nbsp;the&nbsp; &nbsp;patient &nbsp;carefully for&nbsp; &nbsp;complications of neutropenia. Chemotherapy &nbsp;doses should be reduced or maintained as per the instructions for the specific regimen.</p><p>If &nbsp;LVEF &nbsp;drops &nbsp;;,1 0 &nbsp;ejection &nbsp;fraction&nbsp;&nbsp; (EF) points &nbsp;from baseline and to &nbsp;below &nbsp;50%, treatment should &nbsp;be stopped&nbsp; &nbsp;and &nbsp;a &nbsp;repeat&nbsp; &nbsp;LVEF assessment &nbsp;should&nbsp; &nbsp;be performed within &nbsp;approximately 3 &nbsp;weeks. Discontinuation of trastuzumab should be strongly considered if LVEF does not improve, or declines further, or symptomatic &nbsp;congestive heart failure (CHF) develops; unless the benefits outweigh the risks for the individual patient. All&nbsp; &nbsp;such &nbsp;patients &nbsp;should&nbsp; &nbsp;be &nbsp;referred for assessment by a cardiologist and followed up.</p><p>Missed Doses</p><p>For a dose missed by s1 &nbsp;week, administer the usual maintenance &nbsp;dose of trastuzumab &nbsp;(weekly regimen: &nbsp;2 mg/kg; three-weekly &nbsp;regimen: 6 mg/kg), as soon as possible, without waiting till &nbsp;the &nbsp;next &nbsp;planned &nbsp;cycle. Subsequent maintenance &nbsp;doses should &nbsp;then &nbsp;be given according to the previous schedule.</p><p>For a dose missed by &gt;1 week, administer a re-loading dose of trastuzumab &nbsp;(weekly regimen: 4 mg!kg; three&shy; weekly&nbsp; &nbsp;regimen: &nbsp;8 &nbsp;mg/kg) &nbsp;<em>over &nbsp;</em>approximately 90 minutes; &nbsp;subsequent &nbsp;maintenance &nbsp;doses &nbsp;(weekly regimen:&nbsp; &nbsp;2 &nbsp;mg/kg; three-weekly regimen&nbsp; &nbsp;5 &nbsp;mg/kg respectively) should &nbsp;then &nbsp;be &nbsp;given &nbsp;(weekly &nbsp;regimen: every week; three-weekly regimen: every 3 weeks) from that point.</p><p>USE IN SPECIAL POPULATIONS&#39;&middot;&#39;&middot;&quot;</p><p>From &nbsp;available data, disposition of &nbsp;trastuzumab (reference product) &nbsp;is not altered &nbsp;with &nbsp;increasing age, renal impairment or serum creatinine levels. Elderly patients in reported clinical trials did not receive reduced doses.</p><p><em>Pregnancy &nbsp;</em><em>and&nbsp; &nbsp;Lactation &nbsp;</em>(see&nbsp; &nbsp;Warnings and</p><p>Precautions section)</p><p><em>Children</em></p><p>The safety and efficacy of &nbsp;trastuzumab &nbsp;has not &nbsp;been established in &nbsp;paediatric &nbsp;patients &nbsp;(below &nbsp;18 &nbsp;years of age). Trastuzumab should not be used in these patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CONTRAINDICATIONS'
•  Hypersensitivity to trastuzumab, murine proteins or to any other component of CANHERA•
•  Severe dyspnoea at rest due to complications  of advanced malignancy
•  Requiring supplementary oxygen therapy.
See section Composition for a list of components of
CANHERA".
Data   in  the   following section (Warnings and Precautions) has been  taken  from  publicly  available data on trastuzumab (reference product).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>General</em></p><p>Initiate trastuzumab &nbsp;therapy under the supervision of a physician experienced in cancer treatment.</p><p><em>Exacerbation of chemotherapy-induced neutropenia</em></p><p>Incidences of neutropenia,including febrile neutropenia, were reported in clinical &nbsp;trials in patients &nbsp;receiving trastuzumab &nbsp;(reference product) &nbsp;in &nbsp;combination with myelosuppressive chemotherapy &nbsp;as compared to those who &nbsp;received chemotherapy&nbsp; &nbsp;alone. &nbsp;The incidence &nbsp;of septic death was similar among patients who received trastuzumab (reference product) and those who did not. The risk of neutropenia &nbsp;may be slightly increased when trastuzumab &nbsp;is administered &nbsp;with &nbsp;docetaxel &nbsp;following anthracycline therapy.</p><p><em>Infusion-related</em><em> </em><em>reactions</em></p><p>Serious&nbsp; &nbsp;infusion-related &nbsp;reactions to &nbsp;trastuzumab (reference product) &nbsp;infusion &nbsp;have been reported; &nbsp;and include dyspnoea, hypotension, wheezing, bronchospasm, tachycardia,reduced oxygen saturation, hypertension, supraventricular tachyarrhythmia, anaphylaxis, urticaria, angioedema and &nbsp;respiratory distress. The majority &nbsp;of &nbsp;these events occur during &nbsp;or within &nbsp;2.5 hours of the start ofthe first infusion. Patients may be at increased risk of a fatal infusion reaction if they are &nbsp;experiencing &nbsp;dyspnoea at &nbsp;rest,&nbsp; &nbsp;arising from complications &nbsp;of advanced malignancy or comorbidities. Should infusion reactions occur, discontinue trastuzumab infusion or slow the rate of infusion, and observe the patient &nbsp;until&nbsp; the symptoms resolve. Rarely, such reactions culminate in death. &nbsp;Most &nbsp;patients experienced resolution of symptoms and were given further infusions of trastuzumab (reference product). Supportive &nbsp;therapy,&nbsp; &nbsp;such &nbsp;as &nbsp;oxygen, epinephrine, antihistamine, bronchodilators, beta-agonists and corticosteroids, has been successfully used to treat serious reactions (see Undesirable Effects).</p><p>There have also been &nbsp;reports &nbsp;of &nbsp;initial&nbsp; &nbsp;improvement followed &nbsp;by &nbsp;delayed&nbsp; &nbsp;reactions with &nbsp;rapid&nbsp; &nbsp;clinical deterioration. Within &nbsp;hours&nbsp; &nbsp;and &nbsp;up &nbsp;to &nbsp;one &nbsp;week following infusion,deaths&nbsp; have occurred. Very rarely,the onset of infusion &nbsp;symptoms and pulmonary &nbsp;symptoms have occurred more than&nbsp; 6 hours after the start of the infusion. &nbsp;Warn patients of the possibility of such a late onset and instruct them to contact the physician if these symptoms &nbsp;occur. Prior to &nbsp;resumption &nbsp;of &nbsp;trastuzumab (reference product) &nbsp;infusion, &nbsp;the &nbsp;majority &nbsp;of &nbsp;patients who &nbsp;experienced a severe infusion &nbsp;reaction &nbsp;were &nbsp;pre&shy; medicated &nbsp;with &nbsp;antihistamines &nbsp;and/or &nbsp;corticosteroids. While &nbsp;some patients &nbsp;tolerated &nbsp;trastuzumab &nbsp;(reference product) &nbsp;infusions, others had recurrent severe infusion</p><p>reactions despite pre-medications.</p><p><em>Pulmonary</em><em> </em><em>toxicity</em></p><p>Severe pulmonary&nbsp; events &nbsp;have &nbsp;been &nbsp;reported with trastuzumab &nbsp;(reference product), occasionally resulting in death.Cases of interstitial&nbsp; lung diseases including lung infiltrates, &nbsp;acute &nbsp;respiratory &nbsp;distress syndrome, pneumonia, pneumonitis, pleural effusion, respiratory distress, &nbsp;acute &nbsp;pulmonary &nbsp;oedema&nbsp; &nbsp;and &nbsp;respiratory insufficiency have been reported;these events may occur as part of an infusion-related reaction or with &nbsp;a delayed onset.&nbsp; &nbsp;Risk factors&nbsp; &nbsp;associated &nbsp;with&nbsp; &nbsp;interstitial lung disease include prior or concomitant therapy with other anti-neoplastic &nbsp;therapies such as taxanes, gemcitabine, vinorelbine &nbsp;and &nbsp;radiation &nbsp;therapy. &nbsp;Patients may be at greater risk of severe reactions if they have symptomatic intrinsic lung disease; or extensive tumour &nbsp;involvement of &nbsp;the &nbsp;lungs, resulting &nbsp;in dyspnoea at rest. Therefore, such patients &nbsp;should not &nbsp;be treated &nbsp;with &nbsp;trastuzumab (see&nbsp; &nbsp;Contraindication). Exercise &nbsp;caution for pneumonitis,&nbsp; especially &nbsp;in &nbsp;patients being treated concomitantly with taxanes.</p><p><em>Cardiac dysfunction</em></p><p>Trastuzumab therapy increases the risk of CHF (New York Heart Association [NYHA] class II - IV) or asymptomatic cardiac dysfunction. These events have been observed in patients receiving trastuzumab (reference product) alone or in combination with paclitaxel following anthracycline (doxorubicin or epirubicin). These events &nbsp;can be moderate to severe and may be associated with &nbsp;death. Caution should be taken when treating patients with increased cardiac risk (e.g., hypertension, &nbsp;documented coronary artery disease, CHF, LVEF &lt;55%,older age).</p><p>Since the half-life of trastuzumab is long,it may persist in the circulation for up to 27 weeks after stopping treatment. Patients who receive anthracyclines after stopping &nbsp;trastuzumab &nbsp;may possibly be at increased risk of &nbsp;cardiotoxicity. &nbsp;If possible, physicians should avoid anthracycline-based therapy for up to 27 weeks after stopping treatment, and &nbsp;monitor cardiac &nbsp;function carefully if anthracyclines are used. If left ventricular function continues &nbsp;to &nbsp;decrease, but &nbsp;patients &nbsp;remain asymptomatic, the &nbsp;physician should consider discontinuing therapy if no clinical benefit of therapy has been seen. Trastuzumab and anthracycline should not be given &nbsp;concurrently&nbsp; &nbsp;in &nbsp;the &nbsp;adjuvant &nbsp;treatment &nbsp;setting (EBC) or MBC setting. In patients &nbsp;with &nbsp;EBC eligible for neoadjuvant-adjuvant &nbsp;chemotherapy, trastuzumab should only be used concurrently &nbsp;with &nbsp;anthracyclines in chemotherapy-naive patients and only with &nbsp;low-dose anthracycline &nbsp;regimens (maximum &nbsp;cumulative &nbsp;doses of doxorubicin&nbsp; &nbsp;180 &nbsp;mg/m&#39; or &nbsp;epirubicin &nbsp;360 &nbsp;mg!m&#39;).&nbsp;&nbsp; In patients&nbsp; being &nbsp;concurrently &nbsp;treated &nbsp;with full course of low-dose anthracyclines and trastuzumab in the neoadjuvant setting, additional cytotoxic chemotherapy should not be given after surgery.</p><p>Patients who &nbsp;are going to start trastuzumab, especially those with &nbsp;prior &nbsp;exposure to &nbsp;anthracycline and cyclophosphamide, should&nbsp; &nbsp;undergo&nbsp; &nbsp;baseline &nbsp;cardiac assessment, including history and physical examination, ECG, echocardiogram &nbsp;and/or&nbsp; &nbsp;multigated &nbsp;acquisition (MUGA)&nbsp; &nbsp;scan. &nbsp;Repeat &nbsp;cardiac &nbsp;assessments every &nbsp;3 months during treatment and every 6 months following discontinuation of treatment until &nbsp;24 months &nbsp;from the last administration oftrastuzumab.</p><p>If LVEF drops 0!!1 0 EF points from baseline and to below 50%, &nbsp;treatment should be stopped &nbsp;and a repeat LVEF assessment should be performed &nbsp;within approximately 3 weeks. If LVEF does not improve, or declines further, or symptomatic &nbsp;CHF &nbsp;develops, discontinuation &nbsp;of trastuzumab &nbsp;should be strongly considered, unless the benefits for the individual patient outweigh the risks. All such patients &nbsp;should &nbsp;be&nbsp; referred &nbsp;for &nbsp;assessment by a cardiologist and followed up.</p><p>No prospective study has been done &nbsp;on the safety of continuing or resuming trastuzumab (reference product) in patients who&nbsp; experience cardiotoxicity. In the pivotal trials, &nbsp;most patients who &nbsp;developed heart &nbsp;failure improved with &nbsp;standard treatments (including &nbsp;diuretics, cardiac glycosides, beta blockers and/or angiotensin converting enzyme inhibitors). In these trials, most patients with &nbsp;cardiac symptoms who also had evidence of a clinical benefit from trastuzumab (reference product) treatment continued on therapy &nbsp;with trastuzumab (reference &nbsp;product) without further clinical &nbsp;cardiac events.</p><p>In a global early breast cancer trial with trastuzumab (reference product), &nbsp;patients with &nbsp;the&nbsp; &nbsp;following conditions were excluded:</p><p>&bull; History of myocardial infarction</p><p>&bull; Angina pectoris requiring medical treatment</p><p>&bull; Clinically significant cardiac valvular disease</p><p>&bull; History of existing cardiac heart failure (NYHA II</p><p>-IV)</p><p>&bull; Other&nbsp; cardiomyopathy, cardiac arrhythmia requiring medical treatment</p><p>&bull; Poorly controlled hypertension</p><p>&bull; LVEF&lt;55%</p><p>&bull; hemodynamic effective pericardia! effusion Therefore, the benefit-risk &nbsp;balance for such patients &nbsp;is unknown,and treatment is not recommended.</p><p><em>Benzyl alcohol</em></p><p>Benzyl &nbsp;alcohol &nbsp;(1.1 %) &nbsp;is &nbsp;used &nbsp;as &nbsp;a &nbsp;preservative &nbsp;in bacteriostatic water for injection in the 1 50 mg and 440 mg CANHERA&quot;multi-dose vials. If a patient is known to be hypersensitive to benzyl alcohol, reconstitute CANHERA&quot; with &nbsp;water &nbsp;for &nbsp;injection, &nbsp;and use only one dose per CANHERA&quot; vial. Discard any unused portion.</p><p>&nbsp;</p><p>Fertility,pregnancy and lactation</p><p><em>Women of childbearing potential</em></p><p>Women &nbsp;of childbearing &nbsp;potential should be advised to use effective contraception during treatment with trastuzumab &nbsp;and for 7 months &nbsp;after treatment has concluded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Formal drug &nbsp;interaction studies with trastuzumab (reference product) have not been performed in humans. In clinical trials of trastuzumab (reference product), no clinically significant interactions with the concomitant medications &nbsp;used were observed (see Pharmacokinetic Properties). The results of a small sub-study suggested that &nbsp;the &nbsp;exposure &nbsp;to &nbsp;the &nbsp;bioactive &nbsp;metabolites &nbsp;(e.g.,5-fluorouracil) of capecitabine &nbsp;was not affected &nbsp;by concurrent&nbsp; &nbsp;use of &nbsp;cisplatin &nbsp;or &nbsp;by &nbsp;concurrent&nbsp; &nbsp;use of cisplatin plus trastuzumab (reference product). However, capecitabine itself showed higher concentrations &nbsp;and a longer&nbsp; &nbsp;half-life&nbsp; when&nbsp; &nbsp;combined with &nbsp;trastuzumab (reference product). &nbsp;The&nbsp; &nbsp;mean serum trough concentration of trastuzumab &nbsp;(reference product) &nbsp;was consistently &nbsp;elevated&nbsp;&nbsp; approximately 1.5-fold, &nbsp;when administered in combination with paclitaxel as compared to trough &nbsp;concentrations of trastuzumab (reference product) &nbsp;when administered in combination with &nbsp;an anthracycline &nbsp;and cyclophosphamide. Trastuzumab can increase the &nbsp;overall &nbsp;exposure of &nbsp;7-deoxy-13 &nbsp;dihydro&shy; doxorubicinone (D7D), a doxorubicin &nbsp;metabolite. &nbsp;The bioactivity of D7D and the clinical impact of the increase of this metabolite is not clear.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy</em></p><p>Reproduction studies have &nbsp;been &nbsp;performed in cynomolgus monkey at doses up to 25 times the weekly human dose and have revealed no evidence of impaired fertility or harm to the fetus due to trastuzumab. Placental transfer of trastuzumab during the early (days 20-50 of gestation) and late (days 120-150 of gestation) foetal development period was observed. It is not known whether &nbsp;trastuzumab &nbsp;can affect &nbsp;reproductive &nbsp;capacity. As animal reproduction studies are not always predictive of &nbsp;human &nbsp;response, trastuzumab&nbsp; &nbsp;should &nbsp;be &nbsp;avoided during &nbsp;pregnancy &nbsp;unless the &nbsp;potential &nbsp;benefit &nbsp;for &nbsp;the mother outweighs the potential risk to the foetus.</p><p>In &nbsp;the &nbsp;post-marketing &nbsp;setting, &nbsp;cases of &nbsp;foetal&nbsp;&nbsp;renal growth &nbsp;and/or function impairment in association with oligohydramnios, some associated with fatal pulmonary hypoplasia of the foetus,have been reported in pregnant women receiving trastuzumab. Women who become pregnant should be advised of the possibility of harm to the&nbsp; &nbsp;foetus. &nbsp;If &nbsp;a &nbsp;pregnant &nbsp;woman &nbsp;is &nbsp;treated with trastuzumab, or &nbsp;if &nbsp;a patient &nbsp;becomes pregnant &nbsp;while receiving trastuzumab &nbsp;or within 7 months following the last dose of trastuzumab, close monitoring by a multidisciplinary team is desirable.</p><p>&nbsp;</p><p><em>Breast-feeding</em></p><p>A study conducted &nbsp;in lactating Cynomolgus monkeys at doses 25 times that of the weekly human maintenance dose demonstrated &nbsp;that &nbsp;trastuzumab &nbsp;is secreted in the milk. The presence of trastuzumab in the serum of infant monkeys was not associated with &nbsp;any adverse effects on their growth or development &nbsp;from birth &nbsp;to 1 month &nbsp;of age. It is not known &nbsp;whether &nbsp;trastuzumab &nbsp;is secreted in human milk. As human lgG1 is secreted into human milk, and the &nbsp;potential &nbsp;for &nbsp;harm &nbsp;to &nbsp;the infant &nbsp;is unknown, women &nbsp;should not &nbsp;breast-feed during &nbsp;<em>CANHERA&quot;150 </em><em>mg </em>therapy and for 7 months after the last dose.</p><p>&nbsp;</p><p><em>Fertility</em></p><p>There is no fertility data available.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects on Ability to Drive and Use Machines Trastuzumab has no or negligible influence on the ability to drive or use machines. Patients should be advised not to &nbsp;drive &nbsp;and &nbsp;use &nbsp;machines &nbsp;if &nbsp;they &nbsp;are &nbsp;experiencing infusion-related symptoms;until the symptoms abate.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following undesirable effects are based on publicly available &nbsp;information categorized on &nbsp;the &nbsp;basis of frequency of occurrence of adverse reactions in different clinical &nbsp;trials&nbsp; &nbsp;and&nbsp; &nbsp;post-marketing information for trastuzumab (reference product).</p><p><em>Very&nbsp; &nbsp;common (&#39;!!.111 0):&nbsp; &nbsp;</em>Tremor, blood &nbsp;pressure decreased,blood pressure increased, heart beat irregular, palpitation, cardiac flutter, &nbsp;lip &nbsp;swelling, &nbsp;swelling &nbsp;face, muscle tightness (adverse reactions reported &nbsp;largely in association &nbsp;with&nbsp; &nbsp;infusion-related reactions); &nbsp;ejection fraction &nbsp;decreased (observed with &nbsp;combination therapy following anthracyclines and combined &nbsp;with &nbsp;taxanes); wheezing (adverse reactions reported in association with a &nbsp;fatal &nbsp;outcome and&nbsp; &nbsp;infusion-related reactions); dyspnoea (adverse reactions reported in association with a &nbsp;fatal &nbsp;outcome); &nbsp;infection, &nbsp;nasopharyngitis, febrile&nbsp;neutropenia, anaemia, neutropenia, leukopenia, thrombocytopenia, weight decreased/weight loss,anorexia, weight increased, decreased appetite,<br />insomnia, dizziness, headache, paraesthesia, hypoaesthesia, dysgeusia, conjunctivitis, lacrimation increased, lymphoedema, hot flush, cough, epistaxis,<br />rhinorrhoea, oropharyngeal pain, diarrhoea, vomiting, nausea, abdominal pain, dyspepsia, constipation, stomatitis, erythema, rash, alopecia, nail disorder, Palmar-plantar erythrodysaesthesia syndrome, arthralgia, myalgia, asthenia, chest pain, chills, fatigue, influenza-like symptoms, infusion-related reaction, pain, pyrexia, mucosal inflammation, peripheral oedema, nail toxicity.</p><p>Common (?.1 /100 to &lt;1 /10):</p><p>Cardiac failure(congestive), pneumonia, pleural effusion (adverse reactions reported in association with a fatal outcome); supraventricular tachyarrhythmia, hypotension (adverse reactions reported in association with a fatal outcome and infusion-related reactions); neutropenic sepsis, cystitis,<br />herpes zoster, influenza, sinusitis, skin infection, rhinitis, upper respiratory tract infection, urinary tract infection, erysipelas, cellulitis, pharyngitis, hypersensitivity, anxiety, depression, thinking abnormal, peripheral neuropathy, hypertonia, somnolence, ataxia, dry eye, cardiomyopathy, hypertension, vasodilatation, asthma, lung disorder, pancreatitis, haemorrhoids, dry mouth, hepatocellular injury, hepatitis, liver tenderness, acne, dry skin, ecchymosis, hyperhydrosis, maculopapular rash, pruritus, onychoclasis, dermatitis, arthritis, back pain, bone pain, muscle spasms, neck pain, pain in extremity, renal disorder, breast inflammation/mastitis, malaise, oedema, contusion_</p><p><br />Uncommon (?.111,000 to &lt;11100): Sepsis, deafness,<br />pericardia I effusion, urticaria_</p><p><br />Rare (?.1110,000 to &lt;111,000): Paresis, pneumonitis,<br />jaundice.</p><p><br />Not known (cannot be estimated from the available<br />data): Anaphylactic reaction, anaphylactic shock, pulmonary fibrosis, respiratory distress, respiratory failure, lung infiltration, acute pulmonary oedema, acute respiratory distress syndrome, bronchospasm, hypoxia, oxygen saturation decreased (adverse reactions reported in association with a fatal outcome); malignant neoplasm progression, neoplasm progression, hypoprothrombinaemia, hyperkalaemia, brain oedema, papilledema, retinal haemorrhage, cardiogenic shock, pericarditis, bradycardia, gallop rhythm present, laryngeal oedema, pharyngolaryngeal pain, pulmonary hypertension, Herpes simplex, hypokalaemia, dysphagia, accidental injury, thrombosis/embolism, sudden death, autoimmune thyroiditis, flu syndrome, allergic reaction, orthopnoea, pulmonary oedema, interstitial lung disease, hepatic failure, angioedema, dermatitis, urticaria, glomerulonephritis membranous, glomerulonephropathy, renal failure, oligohydramnios, renal hypoplasia, pulmonary hypoplasia. The most serious and/or common adverse reactions reported with trastuzumab (reference product) are: cardiac dysfunction, infusion-related reactions and hypersensitivity, haematological toxicity, infections and pulmonarytoxicity.</p><p><br />Cardiac dysfunction<br />CHF (NYHA II-IV) is a common adverse reaction observed with trastuzumab (reference product) and has been associated with fatal outcome. Signs and symptoms of cardiac dysfunction observed in patients treated with trastuzumab (reference product) include: dyspnoea, orthopnoea, increased cough, pulmonary oedema, 53 gallop or reduced ventricular ejection fraction (see Warnings and Precautions).</p><p>Infusion-related reactions (IRRs) and Hypersensitivity<br />The following infusion-related reactions (IRRs) were seen in all trastuzumab (reference product) trials: chills and/or fever, dyspnoea, hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation and respiratory distress (see Warning and Precautions). Majority of IRRs are mild to moderate in intensity; usually occur during first, second or third infusion and lessen in frequency in subsequent infusions. Anaphylactoid reactions have been observed with trastuzumab (reference product) in isolated cases.</p><p><br />Haematological toxicity<br />Febrile neutropenia is the most common haematological toxicity observed with trastuzumab (reference product). The common haematological toxicity are: anaemia, leukopenia, thrombocytopenia and neutropenia. When trastuzumab is administered with docetaxel following anthracycline therapy, the risk of neutropenia may be slightly increased.</p><p>Infections</p><p>In the adjuvant setting, the most common sites of infections include upper respiratory tract, skin and urinary tract.</p><p><br />Pulmonary toxicity<br />The following pulmonary adverse reactions were observed with trastuzumab (reference product): pulmonary infiltrates, acute respiratory distress syndrome, pneumonia, pneumonitis, pleural effusion, respiratory distress, acute pulmonary oedema and respiratory insufficiency.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no information on overdose from human clinical trials. Single doses greater than 10 mg/kg oftrastuzumab (reference product) alone have not been administered in the clinical trials. Doses up to this level were well tolerated.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacodynamic Properties<br />Pharmacotherapeutic group: Antineoplastic agents,<br />monoclonal antibodies<br />ATC code: L01 XC03&#39;<br />Mechanism of Action&#39;&middot;&#39;&middot;&#39;<br />Trastuzumab is a humanised monoclonallgG 1 antibody produced by recombinant DNA technology; and contains complementarity-determining regions from a mouse antibody (anti-p185) specific for the extracellular domain ofthe human epidermal growth factor receptor 2 protein (HER2), along with human framework sequences.<br />The HER2 receptor becomes constitutive instead of inducible in tumour cells. This is a result of increased cell surface expression/overexpression of HER2 protein caused by HER2 gene amplification. Overexpression is seen in 25% to 30% of primary breast cancers and in 6.8% to42.6% gastric cancers.</p><p>Studies showed that amplification or overexpression of HER2 correlates with shorter disease-free survival.</p><p>Trastuzumab binds to sub-domain IV, a juxta membrane region of HER2&#39;s extracellular domain, with high affinity and specificity. This binding inhibits ligand-independent HER2 signalling and prevents the proteolytic cleavage of its extracellular domain, an activation mechanism of HER2.</p><p>In in-vitro assays and in animals, trastuzumab is reported to have inhibited proliferation of human tumour cells overexpressing HER2. Trastuzumab also preferentially mediates antibody-dependent cell-mediated cytotoxicity (ADCC) on tumour cells overexpressing HER2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetic Properties<br />Two phase 1 studies</p><p>1) Single-center, single-dose, 2- period, randomized, double-blind, cross-over study and<br />2) Single-center, randomized, double-blind, three-arm, parallel-group study were conducted in normal healthy volunteers. Both studies showed that pharmacokinetic profile of CANHERA&quot;was similar to that of trastuzumab (reference product). In addition, a multicenter, doubleblind, randomized, parallel-group, phase Ill study showed that pharmacokinetic, efficacy, safety and immunogenicity profiles of CANHERA&quot; was similar to trastuzumab (reference product) in patients with HER2- positive metastatic breast cancer (MBC).<br />Pharmacokinetics in Special Populations&#39;A&quot;<br />The pharmacokinetics of trastuzumab (reference product) have not been studied specifically in elderly patients, patients with renal impairment, or patients with hepatic impairment. However, in the trials conducted with trastuzumab (reference product), distribution and elimination were not noted to be affected by age and renal impairment (see Dose and Method of&nbsp;Administration).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nonclinical studies (conventional toxicity &nbsp;studies) on CANHERA&quot; did not &nbsp;indicate &nbsp;any special hazard for humans. During conventional single- and repeat-dose toxicity &nbsp;studies of &nbsp;CANHERA&quot; in mice and rabbits, &nbsp;no clinically relevant adverse events were observed at the highest &nbsp;dose &nbsp;levels tested. &nbsp;Local tolerance &nbsp;was &nbsp;also evaluated &nbsp;in &nbsp;these &nbsp;toxicity &nbsp;studies, and &nbsp;no &nbsp;clinically</p><p>&nbsp;</p><p>relevant effects &nbsp;were &nbsp;observed. Two comparative nonclinical studies undertaken &nbsp;in cynomolgus &nbsp;monkeys showed&nbsp; &nbsp;that &nbsp;the &nbsp;pharmacokinetic &nbsp;and &nbsp;toxicokinetic profile of CANHERA&quot;was similar to that of trastuzumab (reference product).</p><p>THERAPEUTIC INDICATIONS Metastatic Breast Cancer</p><p>CANHERA&quot; &nbsp;is &nbsp;indicated &nbsp;for &nbsp;the&nbsp; &nbsp;treatment &nbsp;of &nbsp;MBC</p><p>patients who have human epidermal growth factor receptor 2- (HER2)-overexpressing tumours.</p><p>Early Breast Cancer (EBC)</p><p>CANHERA&quot; is indicated for &nbsp;the &nbsp;treatment of &nbsp;adult patients with HER2 positive EBC.</p><p>CANHERA&quot;should only be used in MBC or EBC patients who have tumours with either overexpression of HER2 or HER2 gene amplification.</p><p>Metastatic Gastric Cancer (MGC)</p><p>CANHERA&quot; in &nbsp;combination with &nbsp;capecitabine&nbsp; &nbsp;or &nbsp;5- fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who &nbsp;have not &nbsp;received &nbsp;prior &nbsp;anti-cancer treatment for their metastatic disease.</p><p>CANHERA&quot;should &nbsp;be used in only those MGC patients whose tumours overexpress HER2,as defined by:</p><p>&bull; IHC2+ plus &nbsp;a confirmatory silver in situ hybridisation (SISH) or fluorescence in situ hybridisation (FISH) result,OR</p><p>&bull; &nbsp;IHC 3+ result.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>List of Excipients:<br />L-Histidine,</p><p>L-Histidine hydrochloride,</p><p>Polyethylene Glycol3350 (Macrogol3350),</p><p>D-Sorbitol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CANHERA&quot; should not be mixed or diluted with other products except those mentioned under Special Precautions for Disposal and Other Handling section. Do not dilute with glucose solutions, since these cause aggregation ofthe protein.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Please refer to carton/label.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>STORAGE AND HANDLING INFORMATION<br />Store vials at 2&quot;C to S&quot;C prior to reconstitution.<br />Store away from light.<br />Vials should not be used beyond the expiration date<br />stamped on the vial; the reconstituted drug solution<br />should be used as given below; and any unused portion<br />must be discarded. DO NOT FREEZE DRUG THAT HAS<br />BEEN RECONSTITUTED.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PACKAGING INFORMATION<br />150 mg CAN HERA&quot; (Single-dose vial)<br />CANHERA&quot; finished product 150 mg is filled in 15 ml USP type 1 glass vial, closed with a halobutyl rubber stopper and sealed with 20MM lavender flip-off seal.<br />150 mg CANHERA&quot;(Multi-dosevial)<br />CANHERA&quot; finished product 150 mg is filled in 15 mL USP type 1 glass vial, closed with a halobutyl rubber stopper and sealed with 20MM lavender flip-off seal.<br />The 150 mg pack is provided with total 1 0 ml bacteriostatic water for injection (containing 1.1% benzyl alcohol as preservative), of which 7.2 ml is to be used for reconstitution.<br />440 mg CANHERA&quot;(Multi-dosevial)<br />CANHERA&quot; finished product 440 mg is filled in 50 mL USP type 1 glass vial closed with a halobutyl rubber stopper and sealed with 20MM lavender flip-off seal.<br />The 440 mg pack is provided with total 20 ml bacteriostatic water for injection (containing 1.1% benzyl alcohol as preservative) for reconstitution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Shelf-life of the reconstituted solution<br />1 SO mg (Single-dose use vial)<br />The reconstituted product is physically and chemically<br />stable for 4S hours at 2&deg;C to soc after dissolving in sterile<br />water for injection (not supplied). From a microbiological<br />safety perspective, the reconstituted solution should be<br />used immediately. Do not freeze the reconstituted<br />solution.<br />440 mg/150 mg (Multi-dose use vials)<br />Reconstituted solutions made with bacteriostatic water<br />for injection, as supplied, are stable (physico-chemically<br />and microbiologically) for 2S days, when refrigerated at<br />2&deg;( to soc. The reconstituted solution is suitable for<br />multiple uses, as it contains preservative. Discard any<br />remaining reconstituted solution after 2S days. Do not<br />freeze the reconstituted solution.<br />Shelf-life of the solution for infusion containing<br />the reconstituted product<br />150 mg (single-dose and multi-dose use vials) and<br />440 mg (multi-dose use vials)<br />Infusion solution (0.9% sodium chloride) containing the<br />reconstituted drug product is physically and chemically<br />CHECKED BY:<br />DATE:<br />stable for 24 hours at 2&deg;C to soc. From the perspective<br />of microbiological safety, the CANHERA&quot; infusion<br />solution should be used immediately, unless<br />reconstitution and dilution have taken place under<br />aseptic conditions. If reconstitution and dilution have<br />taken place under aseptic conditions, the infusion<br />solution can be stored up to 24 hours when refrigerated<br />at 2&deg;C to soc.<br />Special Precautions for Disposal and Other<br />Handling<br />&bull; Appropriate aseptic technique should be used.<br />&bull; Use of other reconstitution solvents should be<br />avoided.<br />Reconstitution details are given in the table below:<br />Table 2: Reconstitution Details of 150 mg<br />(Single- and Multi-dose Use)<br />and 440 mg Vials (Multi-dose Use)<br />Type of Vial Reconstitution<br />150 mg 7.2 ml of sterile<br />(single-dose) water for injection*<br />150 mg 7.2 ml of BWFI<br />(multi-dose) (containing 1.1%<br />benzyl alcohol)<br />440mg 20 ml of BWFI<br />(multi-dose) (containing 1.1%<br />benzyl alcohol)<br />BWFI: bacteriostatic water for injection.<br />*Not supplied<br />Trastuzumab pH<br />mg/ml<br />-21 -6.0<br />-21 -6.0<br />-21 -6.0<br />&bull; During reconstitution, handle CANHERA&quot;<br />carefully. Causing excessive foaming during<br />reconstitution or shaking the reconstituted<br />solution may result in problems with the amount<br />of CAN HERA&quot; that can be withdrawn from the<br />vial.<br />&bull; Do not freeze the reconstituted solution.<br />Instructions for reconstitution-150 mg vial<br />(single -dose via/1<br />1) Slowly inject 7.2 ml of sterile water for injection into<br />the vial containing the lyophilized CAN HERA&quot;, using a<br />sterile syringe. Direct the stream into the lyophilized<br />cake.<br />2) To aid reconstitution, the vial should be swirled gently.<br />DO NOT SHAKE.<br />Instructions for reconstitution-150 mg vial<br />(multi-dose vial)<br />1) Slowly inject 7.2 ml of bacteriostatic water for<br />injection into the vial containing the lyophilized<br />CANHERA&quot;, using a sterile syringe. Direct the stream into<br />the lyophilized cake.<br />2) To aid reconstitution, the vial should be swirled gently.<br />DO NOT SHAKE.<br />Instructions for reconstitution-440 mg vial<br />(multi-dose vial)<br />1) Slowly inject 20 ml of bacteriostatic water for<br />injection into the vial containing the lyophilized<br />CANHERA&quot;, using a sterile syringe. Direct the stream into<br />the lyophilized cake.<br />2) To aid reconstitution, the vial should be swirled gently.<br />DO NOT SHAKE.<br />Slight foaming of the product may be seen upon<br />reconstitution; this is not unusual. The vial should be<br />allowed to stand undisturbed for approximately 5<br />minutes. Reconstituted CANHERA&quot;is a colourless to pale<br />yellow, transparent solution. No particles should be<br />visible.<br />Instructions for dilution:<br />Determine the volume of CAN HERA &quot;solution required:<br />&bull; Based on a loading dose of 4 mg CANHERA&quot;Ikg, or<br />D:\e drive\Jobs G Drive Data\HEALTH CAREIPACKAGING\INTERNATIONAL\CANHERA (SAUDI) SFDA\CANHERA PI FOR MOH SUBMISSION<br />asubsequentweeklydoseof2 mg CANHERA&quot;/kg:<br />Body weight (kg) x dose<br />(4 mglkg for loading or 2 mglkg for maintenance)<br />Volume (mL) = __:____:,~----=-----=---=-----__:__<br />21 (mg/mL, concentration of reconstituted solution)<br />&bull; Based on a loading dose of S mg CANHERA&quot;fkg, or<br />a subsequent 3-weekly dose of 6 mg CANHERA&quot;<br />/kg:<br />Body weight (kg) x dose<br />(8 mglkg for loading or 6 mg/kg for maintenance)<br />Volume (mL) = __::___::_:_ _ _:_ ___:__:, ___ __:__<br />21 (mglmL, concentration of reconstituted solution)<br />&bull; Withdraw the appropriate amount of solution from<br />the vial, and add it to an infusion bag containing<br />250 mL of 0.9% sodium chloride solution.<br />&bull; Glucose/dextrose-containing solutions should not<br />be used.<br />&bull; Mix the solution by inverting the bag gently (to<br />avoid foaming).<br />&bull; Once the infusion is prepared it should be<br />administered immediately.<br />&bull; If diluted aseptically, it may be stored for 24 hours<br />(do not store above 30&deg;().<br />Inspect visually for particulate matter and discoloration<br />prior to administration.<br />No incompatibilities have been observed between<br />trastuzumab and polyvinylchloride, polyethylene or<br />polypropylene bags.<br />Dispose of unused medicinal product in accordance with<br />local regulations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MANUFACTURED BY
Biocon Limited
Special Economic Zone
Plot No.2, 3, 4and 5, PhaseiVBommasandra-
Jigani Link Road,
Bommasandra Post,
Bengaluru - 560 099
MARKETED BY
Biocon Limited
20th KM, Hosur Road
Electronics City
Bengaluru - 560 1 DO
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Leaflet generated October 2018
®-Registered trademark of Biocon Limited.
To report adverse events and/or product complaints visit
our website www.biocon.com or e-mail us at DrugSafety@biocon.com
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>